Form 8-K - Current report:
SEC Accession No. 0001193125-25-159005
Filing Date
2025-07-15
Accepted
2025-07-15 06:16:51
Documents
12
Period of Report
2025-07-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d28638d8k.htm   iXBRL 8-K 33893
  Complete submission text file 0001193125-25-159005.txt   151104

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA verv-20250714.xsd EX-101.SCH 2851
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20250714_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20250714_pre.xml EX-101.PRE 11262
14 EXTRACTED XBRL INSTANCE DOCUMENT d28638d8k_htm.xml XML 3638
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 251123027
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)